1. Home
  2. VIOT vs GLSI Comparison

VIOT vs GLSI Comparison

Compare VIOT & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VIOT

Viomi Technology Co. Ltd

HOLD

Current Price

$1.42

Market Cap

151.6M

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

HOLD

Current Price

$29.73

Market Cap

123.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIOT
GLSI
Founded
2014
2006
Country
China
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.6M
123.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
VIOT
GLSI
Price
$1.42
$29.73
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$50.00
AVG Volume (30 Days)
345.7K
726.4K
Earning Date
03-24-2026
11-14-2025
Dividend Yield
5.50%
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$385,267,177.00
N/A
Revenue This Year
$42.19
N/A
Revenue Next Year
$0.96
N/A
P/E Ratio
$3.53
N/A
Revenue Growth
16.89
N/A
52 Week Low
$1.18
$7.78
52 Week High
$4.33
$34.10

Technical Indicators

Market Signals
Indicator
VIOT
GLSI
Relative Strength Index (RSI) 41.09 58.34
Support Level $1.30 $24.00
Resistance Level $1.42 $32.66
Average True Range (ATR) 0.09 4.13
MACD 0.04 -0.47
Stochastic Oscillator 93.10 70.39

Price Performance

Historical Comparison
VIOT
GLSI

About VIOT Viomi Technology Co. Ltd

Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.

Share on Social Networks: